LEXINGTON, Mass. — August 6, 2025 — Leads & Copy — Voyager Therapeutics, Inc. (Nasdaq: VYGR) reported its second quarter 2025 financial and operating results, highlighting an extended cash runway into 2028 and the addition of an APOE program to its Alzheimer’s disease pipeline.
CEO Alfred W. Sandrock, Jr., M.D., Ph.D., emphasized the company’s potential to drive transformative neurotherapeutics, with expectations of four programs in the clinic next year. Key highlights include:
Cash Runway: Extended into 2028 due to restructuring efforts.
Pipeline Expansion: APOE program added for Alzheimer’s disease.
Partnered Programs: 11 programs with potential for $2.6B in milestone payments.
Financials: Collaboration revenue decreased to $5.2 million, R&D expenses decreased to $31.3 million, and net loss was $33.4 million. Cash position remains strong at $262 million as of June 30, 2025.
Upcoming Milestones: IND submissions for partnered FA and GBA1 programs anticipated in 2025, with clinical trial initiations in 2026. U.S. IND and Canadian CTA submissions anticipated for VY1706 for AD in 2026.
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, smccabe@jpa.com
Media: Adam Silverstein, adam@scientpr.com
Source: Voyager Therapeutics, Inc.
